The Recall Desk
LowFDA (Devices)·Z-1676-2015·Announced 2015-06-03

Biocare Medical Recalls D2-40 Lymphatic Marker Due to Incorrect Instructions

Biocare Medical is recalling 19 units of D2-40 Lymphatic Marker because incorrect Instructions for Use were shipped with the product.

What this means for you

Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.

Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is not likely to cause adverse health consequences. The issue is limited to incorrect documentation (Instructions for Use) without reported injuries or illnesses.

Plain-English summary

Biocare Medical, LLC is recalling 19 units of D2-40 (Lymphatic Marker), a mouse monoclonal antibody intended for laboratory use in the qualitative identification of O-linked sialoglyprotein protein by immunohistochemistry. The recall was initiated because the firm discovered that incorrect Instructions for Use were shipped with one lot of the product.

The affected product is identified by catalog number PM266AA, lot 030615, and an expiration date of 2018/03. The units were distributed worldwide, including in the United States (specifically in Michigan, South Carolina, North Carolina, Arizona, California, Missouri, and Wisconsin) and in Hungary, Spain, and Austria.

Consumers and laboratories should stop using the affected product and contact Biocare Medical for further instructions or a refund.

The recalled product

Product
D2-40 (Lymphatic Marker); For In Vitro Diagnostic; Catalog number: PM266AA Product Usage: In Vitro Diagnostic Use.: a mouse monoclonal antibody that is intended for laboratory use in the qualitative identification of O-linked sialoglyprotein protein by immunohistochemistry (
Affected units
19

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (3)

  • Catalog number: PM266AA
  • lot 030615
  • Expiration: 2018/03.

Distribution

Distributed nationwide across the United States.

The notice also names 7 states specifically: